Allianz Asset Management
IBB icon

Allianz Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Allianz Asset Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,700
Closed -$857K – 2148
2025
Q1 		$857K Hold
6,700
– – ﹤0.01% 1717
2024
Q4 		$886K Hold
6,700
– – ﹤0.01% 1674
2024
Q3 		$976K Hold
6,700
– – ﹤0.01% 1640
2024
Q2 		$920K Buy
+6,700
New +$894K ﹤0.01% 1621

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Allianz Asset Management's IBB Position: Q1 2021 in Review

Allianz Asset Management sold out of iShares Biotechnology ETF (IBB) in Q1 2021, closing a stake of 3,000 shares — an estimated $454K sold.

Allianz Asset Management first reported a position in IBB in Q2 2013 and held it in 28 quarters. The position peaked at $124M in Q2 2013. 845 funds tracked by Wall St. Rank hold IBB as of Q1 2021.

  • Allianz Asset Management reported no remaining iShares Biotechnology ETF position as of Q1 2021 after selling out during the quarter.
  • Allianz Asset Management sold 3,000 iShares Biotechnology ETF shares in Q1 2021, an estimated $454K.
  • Allianz Asset Management first reported a position in iShares Biotechnology ETF in Q2 2013 and held it in 28 quarters.
  • Allianz Asset Management's iShares Biotechnology ETF position peaked at $124M in Q2 2013.
  • 845 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2021.

Based on Allianz Asset Management's 13F filing for Q1 2021, filed 13 May 2021.